RNTX - Latest News
Rein Therapeutics Inc. (RNTX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $21.3M. Beta to the broader market is 1.37.
The article list below shows the most recent RNTX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent RNTX Headlines
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
globenewswire.com - Aug 20, 2026
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression Acti
Brokerages Set Rein Therapeutics Inc. (NASDAQ:RNTX) PT at $6.00
defenseworld.net - Aug 17, 2026
Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report) has earned an average rating of "Hold" from the four brokerages that are presently covering t
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com - Aug 14, 2026
AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
globenewswire.com - Aug 4, 2026
Data support ongoing Phase 2 “RENEW” trial First-in-human clinical study produced measurable reductions in multiple markers of lung scarring and infla
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
globenewswire.com - Jul 21, 2026
AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical
How News Affects RNTX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track RNTX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked RNTX news questions
- What is the latest RNTX news headline?
- The most recent RNTX headline (Aug 20, 2026) is "Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the RNTX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What RNTX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual RNTX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.